Global market launch: TIEFENBACHER PHARMACEUTICALS expands the launch of the anticoagulant medicine Rivaroxaban to Central America and further international markets

We at Tiefenbacher Pharmaceuticals strongly believe that our high-quality medicines should be available for all patients around the world – irrespective of their origin or nationality. That´s why we are happy to share that we have successfully expanded the launch of the generic version of Rivaroxaban to Central America, the Caribbean and Kazakhstan.

Rivaroxaban is an anticoagulant medication (blood thinner) used to treat and prevent blood clots. The tablets are marketed in the strengths 10 mg, 15 mg, and 20 mg by our cooperation partner, one of the biggest generic pharmaceutical companies in the world.

We develop the product in our own laboratories in Hyderabad, India. Tiefenbacher Group already launched the product in certain patent-free European markets before. A launch in further international countries like Thailand, Albania, Serbia, Peru, Chile, and North Macedonia will follow soon. Overall, our country scope covers about 80 countries around the world. With this global market entry, we enable millions of patients worldwide access to a life- improving, high-quality treatment – also in emerging countries where GMP-compliance is not always a standard yet.

Tiefenbacher Pharmaceuticals, a part of Tiefenbacher Group, develops and commercializes generic, value added, and innovative pharmaceuticals as well as medical devices worldwide. We provide over 180+ pharmaceutical products across various therapeutic categories in 10+ dosage forms. With our in-house product development and manufacturing, we can address specific therapeutic needs in unique formulations of prescription drugs (Rx) and over-the-counter (OTC) medicines for global markets (including highly potent drugs).  

For more information about our finished dosage forms and healthcare solutions, please contact Tiefenbacher Pharmaceuticals: or please visit us

Tiefenbacher Pharmaceuticals launch of the generic version of Rivaroxaban (blood thinner) to Central America, the Caribbean and Kazakhstan.
About Tiefenbacher Group – Pioneering Healthcare since 1963

Tiefenbacher Group is a purpose-driven and 100% family-owned healthcare company providing best-in-class solutions along the entire pharmaceutical value chain. From the initial idea to market access of high-quality medicines around the world: We distribute APIs and develop, produce, and register finished dosage forms (FDFs) including highly potent drugs as well as medical devices. Our purpose is to improve people’s lives by making pharmaceuticals more affordable, more available, and better than ever before.

For further information about TIEFENBACHER GROUP and our solutions for better healthcare and our in-house capabilities to develop and commercialize pharmaceutical products for global markets (including highly potent drugs) please contact us by email at or visit us on: